MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS
Clinical trials for MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS trials appear
Sign up with your email to follow new studies for MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to tame rare ovarian cancer
Disease control OngoingThis study tests whether two drugs, fulvestrant and abemaciclib, can help control low-grade serous ovarian cancer in women with advanced disease. Up to 18 participants will receive the combination before surgery. The goal is to see if the cancer shrinks or stops growing, and to c…
Matched conditions: MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
Bacteria bombs target Hard-to-Treat tumors in new cancer trial
Disease control OngoingThis early-phase study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The goal is to find the safest dose and s…
Matched conditions: MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Can avastin stop hidden ovarian cancer after second-look surgery?
Disease control OngoingThis study tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that was still found during a second-look surgery. About 35 adults with advanced-stage cancer who already had standard chemotherapy and surgery will rece…
Matched conditions: MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Experimental combo aims to stall tough cancers
Disease control OngoingThis study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including breast, digestive, female/male genital, and thyroid cancers). The goal is to find the safest dose and see if it can help control the cancer. Up to 9…
Matched conditions: MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
Home workout study aims to help cancer survivors shed pounds
Disease control OngoingThis study looks at whether a home-based weight loss program, with or without resistance training, is practical and helpful for endometrial cancer survivors. Fifteen participants who completed treatment 6 to 36 months ago will try the program for 6 months. The goal is to see if t…
Matched conditions: MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 07, 2026 18:42 UTC